NUVATION BIO INC

NUVBNYSE

🏆 #2004 by market capEarnings Nov 2US Equity

$310.25▲ $14.86 (+4.79%)

Simulated price

🔔

Track NUVB

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 4.8%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$1.97B

Small Cap

📈Revenue Growth (YoY)

+1083.6%

High Growth

📊Gross Margin

88.2%

High

💵FCF Margin

—

⚖️P/S Ratio

11.9x

Elevated

Otter Score

Weak

No chart data available for NUVB.

Trading Snapshot

Day Range: $306.44 – $315.72
52-Week Range: $2.99 – $9.75
Volume: $1.57B
Avg Volume: $1.78B
Shares Outstanding: 348.2M
Next Earnings: Oct 20, 2026

Fundamentals Snapshot

Annual Revenue: $166M
Last Q Revenue: $42M
P/E Ratio: —
P/S Ratio: 11.9x
EPS (TTM): $-0.44
Dividend Yield: —

Why Investors Own NUVB

✓High-growth profile — revenue up +24.1% YoY with expanding US Equity exposure.
✓Healthy economics — 41% gross margin and 22% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

NUVATION BIO INC

NUVB

Financial Trends

Revenue (TTM)

$166M▲ +24.2% YoY

Gross Margin (TTM)

41.3%▲ +1.1% YoY

Operating Income (TTM)

$58M▲ +24.2% YoY

Free Cash Flow (TTM)

$36M▲ +24.2% YoY

StockOtter · stockotter.space

About NUVATION BIO INC

Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.

🦦